Effect of oxandrolone therapy on adult height in Turner syndrome patients treated with growth hormone: a meta-analysis

Nicole M. Sheanon 1* and Philippe F. Backeljauw 1,2

Abstract
Turner syndrome is a chromosomal abnormality in which there is complete or partial absence of the X chromosome. Turner syndrome affects 1 in every 2000 live births. Short stature is a cardinal feature of Turner Syndrome and the standard treatment is recombinant human growth hormone. When growth hormone is started at an early age a normal adult height can be achieved. With delayed diagnosis young women with Turner Syndrome may not reach a normal height. Adjuvant therapy with oxandrolone is used but there is no consensus on the optimal timing of treatment, the duration of treatment and the long term adverse effects of treatment. The objective of this review and meta-analysis is to examine the effect of oxandrolone on adult height in growth hormone treated Turner syndrome patients. Eligible trials were identified by a literature search using the terms: Turner syndrome, oxandrolone. The search was limited to English language randomized-controlled trials after 1980. Twenty-six articles were reviewed and four were included in the meta-analysis. A random effects model was used to calculate an effect size and confidence interval. The pooled effect size of 2.0759 (95% CI 0.0988 to 4.0529) indicates that oxandrolone has a positive effect on adult height in Turner syndrome when combined with growth hormone therapy. In conclusion, the addition of oxandrolone to growth hormone therapy for treatment of short stature in Turner syndrome improves adult height. Further studies are warranted to investigate if there is a subset of Turner syndrome patients that would benefit most from growth hormone plus oxandrolone therapy, and to determine the optimal timing and duration of such therapy.

Keywords: Turner syndrome, Oxandrolone, Growth hormone, Height

Introduction
Turner syndrome (TS) is defined as the complete or partial absence of the second X chromosome in a phenotypic female. The most common features of TS are short stature and gonadal failure. Turner syndrome occurs in 1/2000 live female births. Short stature is one of the cardinal findings in TS, due to haploinsufficiency of the SHOX gene (short stature homeobox-containing gene on the X-chromosome). Growth failure can be seen in early childhood and is usually obvious by 4 years of age. Mean adult height of TS patients without growth hormone (GH) therapy is about 21 cm shorter compared to healthy female adults [1, 2]. Since 1997, the standard treatment for short stature in TS patients has been recombinant human GH. When GH therapy is commenced in early childhood, TS girls can achieve adult height within the normal range [3, 4]. With delayed TS diagnosis, adult height achieved will likely be compromised due to the shorter time period available for catch-up growth. In addition, TS patients often have delayed, incomplete, or absent puberty, and the lack of a pubertal growth spurt further contributes to their adult short stature [5].

Oxandrolone, in addition to GH therapy, has been used as a treatment in TS girls diagnosed at a later age. Oxandrolone, a synthetic anabolic steroid and derivative of testosterone, improves growth by acting directly at the growth plate, and by increasing IGF-I concentrations [6-8]. Oxandrolone has been shown to increase height velocity in girls with TS when combined with GH therapy [3]. The long term beneficial effect of oxandrolone on adult height in TS women has been debated due to the small sample size of previous studies, varied results...
in adult height outcomes, and the concern of virilization due to this treatment [8–13]. A recent review paper summarized results of three placebo-controlled, double-blind, randomized trials investigating the safety and efficacy of oxandrolone in GH-treated girls with TS [14]. The authors concluded that oxandrolone can be used in TS girls who are severely short or have a poor response to GH despite good compliance. They recommend a dose of 0.03–0.05 mg/kg/day starting at the age 8–10 years.

The purpose of our meta-analysis was to conduct a comprehensive statistical review of all available data on adult height in TS girls treated with GH plus oxandrolone versus GH therapy alone. The advantages of such a meta-analysis are a larger sample size, larger statistical power, and an improved estimate of the true effect size.

Methods
A comprehensive literature search was conducted to identify all Randomized Control Trials (RCTs) that investigated adult height in GH-treated TS girls also treated with oxandrolone versus placebo. Relevant trials after 1980 were included. Studies before 1980 were excluded because GH was not introduced until 1985. The following databases were searched using the key words “Oxandrolone” AND “Turner Syndrome”: The Cochrane Database, MEDLINE, EMBASE, and PUBMED. The search was limited by language (English), type of subjects (human), date (1980 to present), and type of trial (RCT). The decision to include only RCTs was made in order to improve the validity of the results and to ensure that only high-quality studies were used. The database search was repeated several times using the combinations of keywords and MeSH terms are listed in Table 1. Bibliographies of the 26 initial articles were reviewed for other relevant articles.

Participants were children and adolescents with TS. The diagnosis of TS was confirmed by karyotype. All of the studies excluded participants with Y chromosome material in the karyotype. Participants were also excluded if they had additional endocrine or metabolic disorders that could affect statural growth except for treated primary hypothyroidism.

The main intervention was oxandrolone. All participants were also on GH either at the same time and/or for several years prior to oxandrolone. All TS subjects were treated with estrogen to induce puberty if clinically indicated (some participants had spontaneous puberty). We felt that it was acceptable to include these patients as long as estrogen replacement was provided in a physiologic manner. The comparison of interest was: GH plus oxandrolone versus GH plus placebo.

The main outcome was growth and included studies which reported adult height, near-adult height, and gain in height. Adult height is the gold standard measure of the efficacy of GH treatment. At the end of the evaluation of all articles only four studies had adult height data and only three studies reported gain in height.

The quality of the articles was assessed formally using the Jadad scale. All of the included studies received a score of 3 or higher. Studies were excluded if: 1- there was not a GH alone or GH + placebo group, 2- adult height or near-adult height data were not reported, or 3- the study had a Jadad score of less than three.

Data was extracted by the primary author. The extraction was completed in duplicate to ensure the data was extracted correctly. There were no discrepancies identified between the two different data extractions. The data extracted included: number of total patients, number of patients in each group, dose of therapies (GH, oxandrolone, placebo, and estrogen), length of therapies, initial height, final height, predicted adult height, and adult height gain. Additional data extracted, when available, included karyotype, baseline skeletal age, and mid-parental height.

The principal measure of effect was mean difference as the data was continuous. The primary outcome was adult height. Studies that did not have adult height data were excluded. The secondary outcome was adult height gain. Studies were excluded from the secondary analysis if adult height gain was not reported or if adult height gain could not be calculated from the data provided.

Two different statistical models were used: Fixed Effects model and Random Effects Model. Heterogeneity between studies was assessed using Cochran Q statistic with a p value of less than or equal to 0.05 indicating significant heterogeneity. Secondary analysis was not indicated as the degree of heterogeneity was not significant. A sensitivity

| Table 1 | Keywords and MeSH terms used for literature search |
|---------|---------------------------------------------------|
| Adolescent | Anabolic Agents/therapeutic use |
| Androgens/adverse effects | Androgens/therapeutic use |
| Body Height/Physiology | Child |
| Double-Blind Method | Female |
| Final Height | Growth Disorder/drug therapy |
| Human Growth hormone/adverse effects | Human Growth hormone/therapeutic use |
| Oxandrolone/therapeutic use | Puberty |
| Time Factors | Turner Syndrome/drug therapy |
| Turner's Syndrome/Ullrich-Turner syndrome | Turner Syndrome/drug therapy |

Sheanon and Backeljauw International Journal of Pediatric Endocrinology Page 2 of 8
analysis was performed by running the Random Effects model using different combinations of the included studies to identify if one study had a greater effect on the results.

Results
The literature search resulted in 26 articles (see Fig. 1). Upon initial review of the abstracts, 9 studies were excluded because the outcome being investigated was not adult height [15–23]. Full-text articles were obtained for the remaining 17 articles. Of these 13 additional articles were excluded because they either involved studies on the same patient cohort reported at different time points [24–30], or the subjects were not all treated with GH [7, 11], or adult height data was not available [12, 13, 31], or there was no control group for GH alone or GH plus placebo [32]. Four articles met criteria and were included in the meta-analysis [3, 33–35]. Bibliographies of these four selected papers were reviewed for other relevant articles; no additional articles were discovered.

The first study was a double-blind, dose–response investigation in which patients were treated with GH from baseline either combined with placebo or oxandrolone (0.03 mg/kg/d or 0.06 mg/kg/day) started at 8 years of age.
At 12–13 years of age all the patients were started on estrogen (except those that progressed spontaneously into puberty). A second study was a prospective RCT in which patients who were on GH were placed on placebo or oxandrolone 0.05 mg/kg/day (max dose 2.5 mg) at an average age of 10.2 years and near adult height was obtained [34]. Patients were randomized to receive estrogen at 12 or 14 years of age (except those with spontaneous puberty). Rosenfeld published several RCT studies on the same cohort of patients. The first phase was observation on no medication, oxandrolone alone, GH alone, or oxandrolone + GH. In the second phase the GH-only group continued on GH while the other 3 groups were placed on GH plus oxandrolone. The initial dose of oxandrolone was 0.125 mg/kg/day but this was decreased after the first year to 0.0625 mg/kg/day due to virilization. Oxandrolone was started at a mean age of 9.2 years. Estrogen therapy was delayed in all subjects until a chronological age of 14 years. Patients were followed until they reached adult height [3]. The fourth study was also a prospective RCT of patients (average age of 10.3 years) on GH alone or GH with oxandrolone (0.1 mg/kg/day). Puberty was induced at a mean age of 14.9 years. The patients were followed for 5 years and only 47/91 had reached adult height at time of publication [35]. Individual study results are summarized in Table 2.

Virilization was the main side effect of oxandrolone that was reported. Girls reported voice deepening, hirsutism, and mild clitoromegaly. In the study by Menke the side effects were reported in 5 % of girls on placebo, 16 % of girls on oxandrolone 0.03 mg/kg/day and in 42 % of girls on oxandrolone 0.06 mg/kg/day [33]. Seven subjects on the higher dose and 1 subject on lower dose oxandrolone discontinued treatment due to the virilization effects. In the study by Gault there were no reports of virilization on a dose of 0.05 mg/kg/day of oxandrolone [34]. Similarly, in the studies by Rosenfeld there were minimal side effects on oxandrolone 0.0625 mg/kg/day, but the dose was reduced from 0.125 mg/kg/day after the first year due to 20 % virilization [3, 27]. In the study by Stahnke there were also reports of virilization (clitoromegaly in 19/44 and deepening of voice in 7/44) but the subjects were on a higher dose of oxandrolone (0.1 mg/kg/day). Considering the data together there is a dose-dependent side effect of virilization with minimal effect with doses of oxandrolone less than 0.06 mg/kg/day.

In each study, for those subjects who did not have spontaneous puberty estrogen was initiated between 12 to 15 years of age. The subjects in the Menke study were started between the age of 12 and 12.99 years on 17-β Estradiol 5 µg/kg/day orally and increased to 10 µg/kg/day after 2 years. Cyclic progesterone was added after at least 2 years of estrogen therapy [33]. The subjects in the Gault study received oral ethinylestradiol starting either at age 12 or 14 years in the following manner: year 1, 2 µg; year 2, 4 µg; year 3, four months of each of 6, 8, and 10 µg. Oral progesterone was started at 15 years of age in all subjects [34]. In the Rosenfeld study estrogen therapy was delayed until a minimum chronological age of 14 years. Oral conjugated estrogens were started at 0.3 mg/day and increased to 0.625 mg/day after 6 months. At 1 year progesterone was added [3]. Finally, in the Stahnke study puberty was induced at an mean age of 14.9 years with estradiol valerate 0.2 mg for the first 6 months and 0.5 mg for the second 6 months. During the second year estradiol was increased to 1 mg and progesterone was started [35]. Each study initiated and titrated estrogen using a slightly different method, but they all used oral estrogens and increased the dose in an incremental fashion in order to simulate natural puberty.

Model results

The Fixed Effects model (FEM) for adult height yielded a population effect size of 2.0621 cm with a standard error of 0.6441 and a 95 % confidence interval of 0.01239–4.1118. The between-study variance was 0.1055. The Random Effects Model (REM) yielded a population effect size of 2.0759 with a standard error of 0.6212 and a 95 % confidence interval of 0.9882–4.0529. The between-study variance was 1.0900. These results are shown in the Forest Plots in Fig. 2a and b. The effect size for each individual study for adult height and height gain are listed in Table 3 along with the variance and confidence intervals.

Heterogeneity was assessed using Cochrane’s Q. The value was 2.5707 with a p value of 0.46 (not significant). A secondary analysis was not performed because there was no significant heterogeneity. The lack of heterogeneity implies that the REM can be used because the difference between the FEM and REM is trivial.

Sensitivity analysis was performed by running the REM and eliminating one study each time to assess if one study was contributing more than the others. The effect size for all 4 studies was 2.0759. The effect size after eliminating the Menke et al. study was 2.3325, after eliminating the Menke et al. study was 2.2966, after eliminating the Rosenfeld et al. study was 2.0950, and after eliminating the Stahnke et al. study was 1.3501. The effect sizes during the sensitivity analysis indicated that the study by Stahnke et al. [35] may have contributed more to the effect size compared to the other studies.

Discussion

This is the first and only meta-analysis examining the effect of oxandrolone therapy on adult height in GH-treated TS girls. Our findings suggest that oxandrolone may have a positive effect on adult height and height gain when used in combination with GH. The effect size may have been larger if the studies had been more similar in the
### Table 2: Individual study results. Descriptive data, Mean and standard deviation for adult height and net height gain

| Study          | Sample size | Mean age baseline yrs (SD) | Mean BA baseline yrs (SD) | Mean MPH | Intervention | Dose of Ox (mg/kg/day) | Mean time on Ox yrs | Mean AH cm (SD) | Mean Ht gain Cm (SD) | Age at estrogen initiation Yrs (SD) | Puberty Sp (%) |
|----------------|-------------|----------------------------|---------------------------|----------|--------------|------------------------|---------------------|-----------------|---------------------|-------------------------------------|--------------|
| Menke [33]     | 42          | 8.5 (4.0)                  | 8.1 (3.6)                 | NR       | GH + Ox      | 0.03                   | 6                   | 156.7 (7.2)     | 9.5 (4.7)           | 12.8 (0.9)                                  | 21           |
|                | 36          | 9.1 (3.5)                  | 8.8 (3.4)                 | NR       | GH + Ox      | 0.06                   | 6                   | 156.5 (5.8)     | 8.3 (4.7)           | 12.7 (0.9)                                  | 24           |
|                | 42          | 9.4 (3.8)                  | 9.0 (3.4)                 | NR       | GH + Placebo | -                      | -                   | 155.6 (5.4)     | 7.2 (4)             | 12.9 (1.0)                                  | 25           |
| Gault [34]     | 47          | 10.2 (1.1)                 | NR                        | NR       | GH + Ox      | 0.05                   | 5                   | 151.06 (4.53)   | -                   | 12 (N = 12) 14 (N = 24)              | 23           |
|                | 52          | 10.3 (0.9)                 | NR                        | NR       | GH + Placebo | -                      | -                   | 149.72 (6.75)   | -                   | 12 (N = 17) 14 (N = 28)              | 13           |
| Rosenfeld [3]  | 45          | 9.9 (2.3)                  | 8                         | 162.5 (4.1) | GH + Ox      | 0.125^a                | 6                   | 152.1 (5.9)     | 10.3 (4.7)          | 14.9 (0.9)                                  | NR           |
|                | 17          | 9.1 (2.1)                  | 8                         | 164.5 (3.7) | GH + Placebo | -                      | -                   | 150.4 (5.5)     | 8.4 (4.5)           | 15.2 (0.9)                                  | NR           |
| Stahnke [35]   | 33          | 11.8 (2.0)                 | 9.9 (1.0)                 | 166.9 (4.0) | GH + Ox      | 0.1^b                  | 4                   | 155.1 (4.5)     | 7.9 (3.8)           | 14.9                                     | NR           |
|                | 38          | 11.7 (1.8)                 | 9.9 (1.1)                 | 163.6 (4.4) | GH + Ox      | 0.1^c                  | -                   | 152.8 (3.8)     | 6.4 (3.5)           | 14.9                                     | NR           |
|                | 20          | 11.5 (1.2)                 | 10.3 (0.5)                | 165.1 (5.5) | GH + Placebo | -                      | -                   | 151.7 (3.1)     | 3.6 (2.6)           | 14.9                                     | NR           |

*AH* adult height, SD standard deviation, Ox oxandrolone, *Ht* height, *BA* bone age, *MPH* mid parental height or target height, NR not reported, Sp spontaneous

^aDose cut in half after the first two years of therapy
^bDose decreased to 0.05 mg/kg/day after the first year
^ctransient oxandrolone group, given ox for < 1 year due to side effects
additional therapies provided (GH and estrogen). However, the lack of heterogeneity found between the studies supports that the differences in dosing and timing of GH and estrogen may not be significant.

Our meta-analysis supports the conclusions from a recent review by Sas et al. [14]. In that paper, data reviewed from three published randomized, placebo-controlled, double-blind studies (which were also included in our meta-analysis) showed that the addition of oxandrolone to GH therapy results in an increase in height velocity and yields a modest increase of adult height [13, 33, 34]. The conclusion was that modest doses of oxandrolone
Adult height and height gain effect size, variance, and confidence intervals

| Study       | Effect Size | Variance | Upper CI | Lower CI |
|-------------|-------------|----------|----------|----------|
| Menke [33]  | 1.1         | 1.93     | 4.957    | −2.757   |
| Gault [34]  | 1.34        | 1.31     | 3.966    | −1.286   |
| Rosenfeld [3] | 1.7        | 2.55     | 6.806    | −3.406   |
| Stahnke [35] | 3.4        | 1.09     | 5.588    | 1.212    |
| Summary     | 2.0759      | 0.6212   | 4.0529   | 0.09882  |

| Study       | Effect Size | Variance | Upper CI | Lower CI |
|-------------|-------------|----------|----------|----------|
| Menke [33]  | 2.3         | 0.91     | 4.114    | 0.486    |
| Rosenfeld [3] | 1.9        | 1.68     | 5.264    | −1.464   |
| Stahnke [35] | 4.3        | 0.78     | 5.851    | 2.749    |
| Summary     | 2.9834      | 0.7796   | 6.3378   | −0.371   |

In this study, puberty was induced later-giving the subjects more time to grow and they reached a taller adult height. It is unclear if the taller height is due to more time for growth, more time on oxandrolone, or more time on GH. Most likely the taller adult height is a result of a combination of these factors. The other factor which cannot be controlled for is the genetic height potential of the patient. Turner syndrome girls with taller parents are more likely to reach a taller adult height compared to girls who have parents of average height. The final limitation was the inability to include additional studies due to missing adult height data. Specifically the study by Zeger, a randomized, double-blind and placebo controlled study, was not included because the raw mean height data and standard deviation data was not available [13]. In this paper they concluded that “the addition of oxandrolone to GH at mean age of 12 (1.7) years augmented height gain after 4 years of treatment.” Those on oxandrolone grew on average 4 cm more than those on placebo [13]. The height gain is greater in the Zeger study than in our meta-analysis; this could be due to the high drop-out rate and only near adult height (defined as bone age ≥ 13.5 years) was assessed. The decision to omit this and other studies was made in order to keep the statistics robust; however, not including these studies could have led to publication bias.

Conclusion

In conclusion, we provide additional evidence that in short TS girls, in whom severe adult height compromise can be expected, combined treatment of GH plus oxandrolone should be considered. We concur with the recommendation that treatment can be started around 8–10 years of age and that this should be done at oxandrolone doses ranging between 0.03 and 0.05 mg/kg/day. Because of the relative paucity of well-executed studies with large enough patient numbers, we suggest that further research still needs to be done to determine the ideal timing of oxandrolone initiation, the duration of treatment with oxandrolone, as well as to better evaluate the long term adverse event profile of this intervention.

Abbreviations

TS: Turner syndrome; GH: Growth hormone; RCT: Randomized control trial; FEM: Fixed effects model; REM: Random effects model.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

NS developed the concept of the proposal under the mentorship of Philippe Backeljauw. NS did the literature search, acquired the data, read the articles and completed the data analysis and interpretation. NS wrote the initial draft of the manuscript and figures, and was involved in the revising and editing the manuscript. PB was involved with the conception of the study. PB was involved with the interpretation of the data and revising and editing the manuscript and figures. Both authors read and approved the final manuscript.

Acknowledgements

We thank Jeffery Welge, PhD, Research Associate Professor of Psychiatry, for his expertise in meta-analysis and his involvement with design and data analysis.
Menke LA, Sas TC, Tianen T, Zandwijken GR, et al. The effect of the weak androgen oxandrolone on psychological and behavioral characteristics in growth hormone-treated girls with Turner syndrome. Horm Behav. 2010;57(3):297–305. doi:10.1016/j.yhbeh.2009.12.011.

Menke LA, Sas TC, Zandwijken GR, de Ridder MA, Stijnen T, de Muinck Keizer-Schrama SM, et al. The effect of oxandrolone on body proportions and body composition in growth hormone-treated girls with Turner syndrome. Clin Endocrinol (Oxf). 2010;72(2):212–9. doi:10.1111/j.1365-2265.2010.03789.x.

Nathwani NC, Hindmarsh PC, Massarano AA, Brock CG. Gonadotrophin pulsatility in girls with the Turner syndrome: modulation by exogenous sex steroids. Clin Endocrinol (Oxf). 1998;49(1):107–13.

Querfeld U, Dopper S, Graehl A, Kloenke P, Wahn F, Zeisel H. Long-term treatment with growth hormone has no persisting effect on lipoprotein(a) in patients with Turner syndrome. J Clin Endocrinol Metab. 1999;84(3):967–70. doi:10.1210/jc.84.3.5516.

Ross JL, Mazzocco MM, Kushner H, Kowal K, Cutler Jr GB, Roeltgen D. Effects of treatment with oxandrolone for 4 years on the frequency of severe arithmetic learning disability in girls with Turner syndrome. J Pediatr. 2009;155(5):714–20. doi:10.1016/j.jpeds.2009.06.031.

Ross JL, Roeltgen D, Stefanatos GA, Feuillan P, Kushner H, Bondy C, et al. Androgen-responsive aspects of cognition in girls with Turner syndrome. J Clin Endocrinol Metab. 2003;88(1):292–6. doi:10.1210/jc.2002-021000.

Schmitt K, Hauser G, Blumel P, Ploch E, Waldhor T, Frisch H. The influence of growth hormone monotherapy and growth hormone in combination with oxandrolone or testosterone on thyroid hormone parameters and thyroxine binding globulin in patients with Ulrich-Turner syndrome. Eur J Pediatr. 1997;156(2):99–103.

Stahnke N, Stubbie P, Keller E. Recombinant human growth hormone and oxandrolone in treatment of short stature in girls with Turner syndrome. Horm Res. 1992;37(Suppl 1):237–46.

Rosenfeld RG, Hintz RL, Johanson AJ, Sherman B, Brasil JA, Burstyn S, et al. Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome. J Pediatr. 1988;113(2):393–400.

Rosenfeld RG, Hintz RL, Johanson AJ, Sherman B. Results from the first 2 years of a clinical trial with recombinant DNA-derived human growth hormone (somatrem) in Turner syndrome. Acta Paediatr Scand. 1990;83(3):305–9.

Rosenfeld RG, Hintz RL, Johanson AJ, Brasil JA, Burstyn S, Chernausek SD, et al. Methionyl human growth hormone and oxandrolone in Turner syndrome: preliminary results of a prospective randomized trial. J Pediatr. 1986;109(6):936–43.

Rosenfeld RG, Frattone RE, Zupke J, Wilson AC, Laron DJ, Monheit GC, et al. Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. J Pediatr. 1992;121(1):49–55.

Rosenfield RG. Acceleration of growth in Turner syndrome patients treated with growth hormone: summary of three-year results. J Endocrinol Invest. 1989;12(Suppl 3):49–51.

Rosenfeld RG. Non-conventional growth hormone therapy in Turner syndrome: the United States experience. Horm Res. 1990;33(4):137–40. Discussion 40–2.

Job JC, Landier F. Three-year results of treatment with growth hormone, alone or associated with oxandrolone, in girls with Turner syndrome. The Kabo collaborative study group. Horm Res. 1991;35(6):229–33.

Nilsson KO, Albertsson-Wikland K, Alm J, Aronson S, Gustafsson J, Hegenas L, et al. Improved final height in girls with Turner syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab. 1996;81(2):349–50.

Menke LA, Sas TC, de Muinck Keizer-Schrama SM, Zandwijken GR, de Ridder MA, Odkin RJ, et al. Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab. 2009;95(5):1511–60. doi:10.1210/jc.2009-0821.

Gault EJ, Perry RJ, Cole TJ, Casey S, Paterson WF, Hindmarsh PC, et al. Effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome: randomised, double blind, placebo controlled trial. BMJ. 2011;342:d1980. doi:10.1136/bmj.d1980.

Stahnke N, Keller E, Landy H, Serog SO. Favorable final height outcome in girls with Ulrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age. J Pediatr Endocrinol Metab. 2002;15(2):129–38.